Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IMG-007 in Healthy Participants
NCT05353972Phase 1Completed
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IMG-007 in atopic dermatitis (AD) and alopecia areata (7 cohorts). Primary endpoint: Incidence and severity of treatment-emergent adverse events at 127 days. Started Jul 2022; status: completed.
02
Drugs
IMG-007
03
Conditions
atopic dermatitis (AD)alopecia areata
Beyond the preview
Go deeper on NCT05353972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353972.